Novavax, Inc., a biotechnology company, focuses on the discovery, development and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company is headquartered in Gaithersburg, Maryland.
| Revenue (TTM) | $413.80M |
| Gross Profit (TTM) | $-10.58M |
| EBITDA | $-101.55M |
| Operating Margin | -89.60% |
| Return on Equity | -898.00% |
| Return on Assets | -6.51% |
| Revenue/Share (TTM) | $2.54 |
| Book Value | $-0.79 |
| Price-to-Book | 41.23 |
| Price-to-Sales (TTM) | 4.30 |
| EV/Revenue | 2.879 |
| EV/EBITDA | 2.36 |
| Quarterly Earnings Growth (YoY) | -38.10% |
| Quarterly Revenue Growth (YoY) | -76.30% |
| Shares Outstanding | $164.95M |
| Float | $146.21M |
| % Insiders | 5.05% |
| % Institutions | 66.33% |
Volatility is currently contracting
Novavax shares fall 8% despite Q3 earnings and revenue beat as costs decline, while a Sanofi milestone drives a sharp increase in its 2026 outlook.
Novavax NASDAQ: NVAX raised its 2026 revenue framework after partner Sanofi began a late-stage trial of a combination influenza and COVID-19 vaccine in Europe, triggering a $125 million milestone payment for the vaccine technology company.
Novavax, Inc. (NVAX) Q3 2026 Earnings Call Transcript
Novavax (NVAX) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.37. This compares to a loss of $0.62 per share a year ago.
Reports total revenue of $68 million for the third quarter of 2026 Raises full-year 2026 Non-GAAP Adjusted Total Revenue by $145 million to $400 million at mid-point and improves GAAP Combined R&D and SG&A expense guidance by $5 million at mid-point In October, Novavax earned a $125 million milestone upon Sanofi's launch of Phase 3 influenza-COVID-19 combination vaccine trial in Europe Sanofi confirms their intent to initiate a U.S. Phase 3 influenza-COVID-19 combination vaccine trial in 2027 to support U.S. approval Differentiated C. difficile vaccine program anticipated to advance into the clinic as early as 2027 Multiple Novavax and partner-led experiments with Matrix-M ® currently underway in a wide array of infectious disease targets and oncology models Company to host conference call today at 8:30 a.m.
Novavax (NVAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The global flu and COVID-19 markets have a current combined value that exceeds $10 billion, with significant burden of disease 1 The combination vaccine candidate evaluated in this trial pairs Sanofi's leading high-dose flu vaccine with Novavax's differentiated COVID-19 vaccine Significant potential value remains in Sanofi partnership via additional future opportunities for milestones and royalties GAITHERSBURG, Md., Oct. 29, 2026 /PRNewswire/ -- Novavax (Nasdaq: NVAX) has earned a $125 million milestone payment with the initiation (fifth patient dosed) of Sanofi's Phase 3 influenza-COVID-19 combination vaccine trial utilizing Novavax's COVID-19 vaccine, Nuvaxovid™.
GAITHERSBURG, Md., Oct. 29, 2026 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that the Company plans to release its third quarter 2026 financial results before the open of the U.S. financial markets on Thursday, November 5, 2026.
Shrugging off a valuation downgrade, Moderna (NASDAQ:MRNA | MRNA Price Prediction) is climbing as investors weigh strong cancer vaccine data against a share price that already reflects big expectations. Moderna stock stands at $217, up 4% this morning.
Novavax (NVAX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on NVAX and any ticker you trade — then tracks every position and per-strategy win rate.
